SG11202000029PA - Anti-tnfalpha-antibodies and functional fragments thereof - Google Patents

Anti-tnfalpha-antibodies and functional fragments thereof

Info

Publication number: SG11202000029PA
Authority: SG; Singapore
Prior art keywords: tnfalpha; antibodies; functional fragments; fragments; functional
Prior art date: 2016-03-17

Application number

SG11202000029PA

Other languages

English (en)

Inventor

Tea Gunde

Sebastian Meyer

Esther Maria Furrer

Original Assignee

Tillotts Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-03-17

Filing date

2017-03-16

Publication date

2020-02-27

2017-03-16 Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag

2020-02-27 Publication of SG11202000029PA publication Critical patent/SG11202000029PA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SG11202000029PA 2016-03-17 2017-03-16 Anti-tnfalpha-antibodies and functional fragments thereof SG11202000029PA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP16160918.5A EP3219727B1 (en)	2016-03-17	2016-03-17	Anti-tnf alpha-antibodies and functional fragments thereof
PCT/EP2017/056246 WO2017158097A1 (en)	2016-03-17	2017-03-16	Anti-tnfalpha-antibodies and functional fragments thereof

Publications (1)

Publication Number	Publication Date
SG11202000029PA true SG11202000029PA (en)	2020-02-27

Family

ID=55542579

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202000029PA SG11202000029PA (en)	2016-03-17	2017-03-16	Anti-tnfalpha-antibodies and functional fragments thereof

Country Status (27)

Country	Link
US (1)	US10975143B2 (es)
EP (2)	EP3219727B1 (es)
JP (1)	JP7126485B2 (es)
KR (1)	KR102474765B1 (es)
CN (1)	CN109071651B (es)
AR (1)	AR107916A1 (es)
BR (1)	BR112018067713A2 (es)
CA (1)	CA3011786A1 (es)
CY (1)	CY1123781T1 (es)
DK (1)	DK3219727T3 (es)
EA (1)	EA201892097A1 (es)
ES (1)	ES2843974T3 (es)
HR (1)	HRP20210120T1 (es)
HU (1)	HUE052869T2 (es)
IL (1)	IL261140B2 (es)
JO (1)	JOP20170063B1 (es)
LT (1)	LT3219727T (es)
MA (1)	MA43738A (es)
PL (1)	PL3219727T3 (es)
PT (1)	PT3219727T (es)
RS (1)	RS61412B1 (es)
SG (1)	SG11202000029PA (es)
SI (1)	SI3219727T1 (es)
SM (1)	SMT202000703T1 (es)
TW (1)	TWI758280B (es)
UY (1)	UY37158A (es)
WO (1)	WO2017158097A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT3219726T (pt)	2016-03-17	2020-12-15	Tillotts Pharma Ag	Alfa-anticorpos anti-tnf e fragmentos funcionais dos mesmos
CA3011502A1 (en)	2016-03-17	2017-09-21	Numab Innovation Ag	Anti-tnf.alpha.-antibodies and functional fragments thereof
US10787508B2 (en)	2016-03-17	2020-09-29	Numab Innovation Ag	Anti-TNFα-antibodies and functional fragments thereof
KR102616436B1 (ko)	2016-12-14	2023-12-27	비오라 쎄라퓨틱스, 인크.	Tnf 저해제로의 위장관 질환의 치료
US11352432B2 (en) *	2017-03-09	2022-06-07	Mab Discovery Gmbh	Antibodies specifically binding to human IL-1R7
EP3810095A1 (en)	2018-06-20	2021-04-28	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2020051275A1 (en) *	2018-09-05	2020-03-12	The Board Of Regents Of The University Of Texas System	Monoclonal antibodies against endotrophin and the use thereof
CN116726362A (zh)	2018-11-19	2023-09-12	比奥拉治疗股份有限公司	用生物治疗剂治疗疾病的方法和装置
WO2020114616A1 (en)	2018-12-07	2020-06-11	Tillotts Pharma Ag	Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
US11707610B2 (en)	2019-12-13	2023-07-25	Biora Therapeutics, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
EP0710719B1 (en)	1990-01-12	2007-03-14	Amgen Fremont Inc.	Generation of xenogeneic antibodies
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es)	1990-08-29	2006-02-16	Genpharm International, Inc.	Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
GB9109645D0 (en)	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
US5919452A (en)	1991-03-18	1999-07-06	New York University	Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
IE922437A1 (en)	1991-07-25	1993-01-27	Idec Pharma Corp	Recombinant antibodies for human therapy
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
ES2313867T3 (es)	1991-12-02	2009-03-16	Medical Research Council	Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos.
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
NO309690B1 (no)	1995-01-23	2001-03-12	Western Atlas Int Inc	Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
AU5632296A (en)	1995-04-27	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
WO1996034096A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
EP0942968B1 (en)	1996-12-03	2008-02-27	Amgen Fremont Inc.	Fully human antibodies that bind EGFR
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
ATE200679T1 (de)	1997-04-14	2001-05-15	Micromet Ag	Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
PT1135498E (pt)	1998-11-18	2008-04-30	Genentech Inc	Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
US7431927B2 (en)	2005-03-24	2008-10-07	Epitomics, Inc.	TNFα-neutralizing antibodies
US7592429B2 (en) *	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
EP1891110A2 (en)	2005-06-07	2008-02-27	Esbatech AG	STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
ES2861592T3 (es)	2008-06-25	2021-10-06	Novartis Ag	Anticuerpos estables y solubles que inhiben el TNF
WO2009155726A2 (en)	2008-06-25	2009-12-30	Esbatech, An Alcon Biomedical Research Unit Llc	Humanization of rabbit antibodies using a universal antibody framework
CN102088958A (zh)	2008-07-10	2011-06-08	艾斯巴技术,爱尔康生物医药研究装置有限责任公司	用于大分子的增强的递送的方法和组合物
RU2012147249A (ru) *	2010-04-07	2014-05-20	Эббви Инк.	TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
WO2012007880A2 (en) *	2010-07-16	2012-01-19	Ablynx Nv	Modified single domain antigen binding molecules and uses thereof
RU2556815C2 (ru) *	2010-09-30	2015-07-20	Чэнду Канхун Байотекнолоджис Ко., Лтд.	ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К ФНО-α, ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ (Fab) И ИХ ПРИМЕНЕНИЕ
CN107188963A (zh) *	2010-10-29	2017-09-22	第三共株式会社	新的抗dr5抗体
EA033643B1 (ru) *	2012-12-05	2019-11-12	Novartis Ag	Антитело к эритропоэтину или его антигенсвязывающий фрагмент
WO2014206561A1 (en)	2013-06-26	2014-12-31	Numab Ag	Novel antibody frameworks
WO2015065987A1 (en) *	2013-11-01	2015-05-07	Ibc Pharmaceuticals, Inc.	Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
US9737623B2 (en) *	2013-12-11	2017-08-22	Cytomx Therapeutics, Inc.	Antibodies that bind activatable antibodies and methods of use thereof
US10233238B2 (en) *	2014-03-26	2019-03-19	Cell Medica Switzerland Ag	TNF alpha antibody or fragment thereof and methods of use
PT3219726T (pt)	2016-03-17	2020-12-15	Tillotts Pharma Ag	Alfa-anticorpos anti-tnf e fragmentos funcionais dos mesmos
US10787508B2 (en)	2016-03-17	2020-09-29	Numab Innovation Ag	Anti-TNFα-antibodies and functional fragments thereof
CA3011502A1 (en)	2016-03-17	2017-09-21	Numab Innovation Ag	Anti-tnf.alpha.-antibodies and functional fragments thereof

2016
- 2016-03-17 ES ES16160918T patent/ES2843974T3/es active Active
- 2016-03-17 SM SM20200703T patent/SMT202000703T1/it unknown
- 2016-03-17 PT PT161609185T patent/PT3219727T/pt unknown
- 2016-03-17 SI SI201631041T patent/SI3219727T1/sl unknown
- 2016-03-17 PL PL16160918T patent/PL3219727T3/pl unknown
- 2016-03-17 DK DK16160918.5T patent/DK3219727T3/da active
- 2016-03-17 HU HUE16160918A patent/HUE052869T2/hu unknown
- 2016-03-17 LT LTEP16160918.5T patent/LT3219727T/lt unknown
- 2016-03-17 EP EP16160918.5A patent/EP3219727B1/en active Active
- 2016-03-17 RS RS20210140A patent/RS61412B1/sr unknown
2017
- 2017-03-16 EP EP17712725.5A patent/EP3430045B1/en active Active
- 2017-03-16 EA EA201892097A patent/EA201892097A1/ru unknown
- 2017-03-16 MA MA043738A patent/MA43738A/fr unknown
- 2017-03-16 JP JP2019500014A patent/JP7126485B2/ja active Active
- 2017-03-16 KR KR1020187026446A patent/KR102474765B1/ko active Active
- 2017-03-16 WO PCT/EP2017/056246 patent/WO2017158097A1/en active Application Filing
- 2017-03-16 US US16/085,543 patent/US10975143B2/en active Active
- 2017-03-16 JO JOP/2017/0063A patent/JOP20170063B1/ar active
- 2017-03-16 CN CN201780015299.XA patent/CN109071651B/zh active Active
- 2017-03-16 BR BR112018067713A patent/BR112018067713A2/pt unknown
- 2017-03-16 CA CA3011786A patent/CA3011786A1/en active Pending
- 2017-03-16 SG SG11202000029PA patent/SG11202000029PA/en unknown
- 2017-03-17 UY UY0001037158A patent/UY37158A/es not_active Application Discontinuation
- 2017-03-17 TW TW106108829A patent/TWI758280B/zh active
- 2017-03-17 AR ARP170100674A patent/AR107916A1/es unknown
2018
- 2018-08-13 IL IL261140A patent/IL261140B2/en unknown
2021
- 2021-01-22 CY CY20211100049T patent/CY1123781T1/el unknown
- 2021-01-22 HR HRP20210120TT patent/HRP20210120T1/hr unknown

Also Published As

Publication number	Publication date
LT3219727T (lt)	2021-02-10
KR102474765B1 (ko)	2022-12-06
CN109071651B (zh)	2022-08-30
SMT202000703T1 (it)	2021-01-05
IL261140A (en)	2018-10-31
TWI758280B (zh)	2022-03-21
US10975143B2 (en)	2021-04-13
HUE052869T2 (hu)	2021-05-28
EA201892097A1 (ru)	2019-02-28
BR112018067713A2 (pt)	2019-01-08
AR107916A1 (es)	2018-06-28
CN109071651A (zh)	2018-12-21
DK3219727T3 (da)	2021-01-04
UY37158A (es)	2017-10-31
CY1123781T1 (el)	2022-05-27
EP3219727A1 (en)	2017-09-20
ES2843974T3 (es)	2021-07-21
EP3430045A1 (en)	2019-01-23
CA3011786A1 (en)	2017-09-21
JOP20170063B1 (ar)	2021-08-17
SI3219727T1 (sl)	2021-04-30
HRP20210120T1 (hr)	2021-03-05
MA43738A (fr)	2018-11-28
RS61412B1 (sr)	2021-03-31
EP3430045B1 (en)	2023-08-23
IL261140B (en)	2022-12-01
PL3219727T3 (pl)	2021-05-17
US20200299375A1 (en)	2020-09-24
KR20180118671A (ko)	2018-10-31
TW201739765A (zh)	2017-11-16
PT3219727T (pt)	2021-01-21
EP3219727B1 (en)	2020-12-16
IL261140B2 (en)	2023-04-01
JP2019512269A (ja)	2019-05-16
JP7126485B2 (ja)	2022-08-26
WO2017158097A1 (en)	2017-09-21

Publication	Publication Date	Title
IL261140B (en)	2022-12-01	Antibodies against tnf-alpha and functional fragments thereof
ZA202108600B (en)	2022-03-30	Anti-tnfalpha-antibodies and functional fragments thereof
IL261261A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
HK1247122A1 (zh)	2018-09-21	組合及其用途
IL261098A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
IL254241A0 (en)	2017-10-31	Etv2 and its uses
IL261793A (en)	2018-10-31	Anti-tnfalpha antibodies and their functional parts
IL264473A (en)	2019-02-28	GPR156 variants and their uses
AU2017235061A1 (en)	2017-09-21	Anti-TNFalpha-antibodies and functional fragments thereof
GB201707279D0 (en)	2017-06-21	Multiearphones and polyearphones
GB2545167B (en)	2022-02-16	Cloches and use thereof
GB201500278D0 (en)	2015-02-25	Novel combination and use